ADC Deals Are Up 1900% in 2026 — Here's the Data

Twenty ADC deals closed between January 22 and July 22, 2026 — a 1900% increase over the single deal recorded in the prior six-month window (July 22, 2025 to January 22, 2026). This is not a gentle uptick. This is a land grab. Big Pharma is backfilling oncology pipelines with next-generation conjugate assets at a pace that hasn't been seen since the post-Enhertu licensing frenzy, and the velocity is compressing timelines, inflating upfronts, and reshaping what a competitive ADC term sheet looks like in real time.

The Data — ADC Deal Activity, Period over Period

The base period was unusually quiet — one deal in six months — which inflates the percentage. But the absolute number tells a clear story on its own: 20 ADC licensing deals in half a year is a historically dense cluster. For context, DealForma tracked roughly 30–35 ADC deals across all of 2024. We're on pace to blow past that by year-end 2026. The ADC deal trends 2026 has produced aren't just a correction from a slow prior period. They represent a structural acceleration.

What's Driving the Trend

Three forces are converging. First, clinical validation is broadening. ADCs are no longer a one-target, one-payload story. The field has moved decisively beyond HER2 and Trop-2 into novel targets — B7-H3, Claudin 18.2, Nectin-4 combinations, and tumor-agnostic approaches — with enough Phase 2 data to justify large upfront commitments. The Novartis-Myricx deals (totaling $2.6B in combined deal value across two agreements) are a direct signal: pharma is paying for differentiated linker-payload chemistry, not just targets.

Second, Big Pharma pipeline anxiety is acute. The 2026–2029 patent cliff is well-documented — roughly $200B in revenue at risk across the top 20 pharma companies. Oncology remains the highest-value therapeutic area for replacement revenue. ADCs sit at the intersection of proven commercial models (Enhertu exceeded $4B in 2025 sales) and genuine mechanistic innovation. Every major pharma company without a next-gen ADC platform is now a buyer. That competitive tension is exactly what's pushing total deal values north of $1B as a baseline for differentiated assets.

Third, capital markets are enabling supply. Biotech funding recovered meaningfully in late 2025, and ADC-focused companies have been disproportionate beneficiaries. Companies like Biocytogen and Myricx Bio have been able to advance assets far enough to command real licensing terms rather than fire-sale acquisitions. The ADC licensing 2026 wave is partly a function of more licensors reaching the inflection point where out-licensing beats dilutive equity raises.

Notable Deals

GSK-Hansoh ($185M upfront / $1.7B TDV) is the marquee transaction. GSK has been systematically rebuilding its oncology pipeline post-Blenrep setback, and the $185M upfront signals serious conviction — that's top-decile for a licensing deal in this modality. The 10.9% upfront-to-TDV ratio is within the range we track for late-preclinical / early Phase 1 ADC assets on our Deal Benchmarks platform, which suggests Hansoh's asset has meaningful clinical-stage data backing the premium.

Novartis-Myricx Bio (two deals, $1.5B + $1.1B TDV) is arguably more interesting structurally. Novartis signed two separate agreements with the same licensor on the same day, likely covering distinct targets or payload technologies. The combined $2.6B in deal value for a single platform partner is unusual and points to a platform-level acquisition strategy without the governance complications of an outright M&A. Upfront terms weren't disclosed, but the deal structure — two parallel agreements — gives Novartis optionality while locking out competitors. Smart.

Biocytogen-Whitehawk ($500M TDV) is noteworthy for the buyer profile. Whitehawk is not a traditional top-20 pharma acquirer, which signals that ADC deal-making has expanded beyond the usual suspects. Mid-cap and specialty pharma players are now competing for assets, which compresses supply and drives terms higher for licensors.

What This Means for BD Teams Right Now

If you're selling an ADC asset, this is a generational seller's market — but the window has a shelf life. Twenty deals in six months means buyers are actively deploying. Competitive processes are your best friend. If you're running a bilateral negotiation for a differentiated ADC platform right now, you're leaving money on the table. Run an auction. The GSK-Hansoh upfront of $185M is a viable comp for late-preclinical assets with novel targets. Use it. Benchmark your own deal terms against the current market on the Ambrosia Deal Calculator.

If you're buying, speed and structure matter more than price negotiation. The days of extracting punitive option structures from cash-strapped ADC biotechs are over, at least in this cycle. Biotechs have alternatives — other pharma partners, public markets, and crossover investors who understand the modality. The Novartis-Myricx dual-deal structure is a template worth studying: it locks in platform access without paying acquisition premiums, preserves the licensor's independence (and motivation), and creates milestone-driven optionality. Consider platform deals over single-asset licenses if your pipeline gap is broad.

Deal structures are shifting. We're seeing higher upfronts as a percentage of TDV compared to 2024 ADC deals, which averaged roughly 7–9% upfront-to-TDV. The GSK-Hansoh deal at ~10.9% reflects competitive pressure. Expect opt-in structures and co-development rights to become more common as licensors push for value participation beyond milestones. Royalty rates on ADC deals are also creeping upward — low-to-mid teens for differentiated assets is the new floor, up from high single digits two years ago.

One caution for both sides: 1900% growth from a base of 1 is volatile, not necessarily sustainable. If clinical setbacks hit any of the major programs licensed in this wave, sentiment can reverse fast. Structure your deals with downside protection — acceleration clauses, reversion rights, and clearly defined go/no-go decision points. The exuberance is justified by science, but not every asset in a 20-deal cluster will succeed.

Benchmark your deal against current ADC market rates using the Ambrosia Deal Calculator — updated weekly with the latest disclosed terms, comps, and modality-specific pricing data.